Targeting obesity-related dysfunction in hormonally driven cancers

por Rubinstein, Maria M., Brown, Kristy A., Iyengar, Neil M.
Publicado 2021

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma

por Shen, Sherry, Rubinstein, Maria M., Park, Kay J., Konner, Jason A., Makker, Vicky
Publicado 2021

Management of thymoma‐associated pure red cell aplasia: A novel use of blood substitute HBOC‐201 in a Jehovah’s Witness

por Rubinstein, Maria M., Goss, Cheryl, Avecilla, Scott T., Dubé, Gregory P., Riely, Gregory J., Mones, Jodi V.
Publicado 2019

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

por Navitski, Anastasia, Al-Rawi, Duaa H., Liu, Ying, Rubinstein, Maria M., Friedman, Claire F., Rampal, Raajit K., Mandelker, Diana L., Cadoo, Karen, O'Cearbhaill, Roisin E.
Publicado 2021

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

por Rubinstein, Maria M., Doria, Eric Rios, Konner, Jason, Lichtman, Stuart, Zhou, Qin, Iasonos, Alexia, Sarasohn, Debra, Troso-Sandoval, Tiffany, Friedman, Claire, O'Cearbhaill, Roisin, Cadoo, Karen, Kyi, Chrisann, Cohen, Seth, Soldan, Krysten, Billinson, Eric, Caird, Imogen, Jang, Dasom, Eid, Khalil, Shah, Pooja, Guillen, Joyce, Aghajanian, Carol, Zamarin, Dmitriy, Makker, Vicky
Publicado 2023